Compare Goodyear Tire & Rubber Co (GT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

The Goodyear Tire & Rubber Company (GT) trades at $4.69, near its 52-week low, with a bearish technical signal and mixed earnings history. Despite beating EPS estimates in two recent quarters, the company reported a net loss of $1.72 billion in 2025, with negative profit margins and ROE. Cash flow improved slightly in 2025, but high debt levels and declining revenue pose challenges. Recent news highlights restructuring efforts and a 'shrink-to-grow' strategy targeting premium tire segments.

GT presents a high-risk opportunity with a deep value proposition—low P/E and P/B ratios suggest undervaluation, but persistent losses and bearish analyst sentiment indicate significant headwinds. The stock's upside hinges on successful execution of its turnaround plan and margin improvement, while downside risks include ongoing volume pressure and macroeconomic pressures on the auto industry.

Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.

The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.